<DOC>
	<DOCNO>NCT00424840</DOCNO>
	<brief_summary>The primary objective phase I study define maximum tolerate dose ( MTD ) weekly bortezomib combination Carboplatin Bevacizumab The primary objective phase II study estimate efficacy ( response rate progression free survival ) safety combination therapy Carboplatin , bortezomib bevacizumab first line therapy patient advance NSCLC . The secondary objective study estimate time progression , duration response , overall survival</brief_summary>
	<brief_title>Phase I/II Study Evaluate Efficacy Safety Combination Chemotherapy</brief_title>
	<detailed_description>Patient population Stage IIIB pleural effusion stage IV Non-Small Cell Lung Cancer . No prior chemotherapy . Specific inclusion exclusion criterion detailed section 3.2 . Number patient Phase I : 9-18 patient Phase II : 19-55 patient A maximum 55 patient ( range 31-55 ) . Study design methodology The study two phase . The phase I use traditional dose escalation model ( 3-6 patient per dose level ) determine maximum tolerate dose ( MTD ) . In phase II portion , optimal two-stage design phase II clinical trial describe Simon et al . utilized ( 33 ) . Treatments administer In phase I , three dose level weekly bortezomib study conjunction fix dose carboplatin bevacizumab 21 day cycle define maximum tolerate dose ( MTD ) . A maximum six cycle administer . Patients complete response , partial response stable disease six cycle allow continue single agent bevacizumab every 3 week maintenance therapy disease progression . If dose limit toxicity ( DLT ) observe 3 patient first cycle , next dose level accrue . If 1 DLT observe , 3 additional patient accrue dose level . If additional DLTs observe , next dose level accrue . However , 2 DLTs observe give dose level , MTD define . MTD define dose ≥2 DLTs observe . NUMBER OF EVALUABLE PATIENTS WITH UNACCEPTABLE TOXICITIES NEXT DOSE LEVEL 0/3 Accrue 3 new patient next high dose level . 1/3 Accrue additional 3 patient current dose level . 1/3 + 0/3 Accrue 3 new patient next dose level . 1/3 + 1/3 Accrue 3 new patient previous dose level ( 3 patient enrolled cohort . If 6 patient enrol already , declare Previous dose MTD ) . 1/3 + 2/3 Stop : Previous dose = MTD 2/3 Stop : Previous dose = MTD The following three level study : Level I ( q21d cycle ) : D1 : carboplatin AUC 6 , bevacizumab 15 mg/kg , bortezomib 1.3 mg/m2 D8 : bortezomib 1.3 mg/m2 Level II ( q21d cycle ) : D1 : carboplatin AUC 6 , bevacizumab 15 mg/kg , bortezomib 1.6 mg/m2 D8 : bortezomib 1.6 mg/m2 Level III ( q21d cycle ) : D1 : carboplatin AUC 6 , bevacizumab 15 mg/kg , bortezomib 1.8 mg/m2 D8 : bortezomib 1.8 mg/m2 If 2 DLT observe Level 1 , level -1 accrue . Level -1 : ( q21d cycle ) : D1 : carboplatin AUC 6 , bevacizumab 15 mg/kg , bortezomib 1 mg/m2 D8 : bortezomib 1 mg/m2 In phase II , either level III MTD dose level use q21day cycle evaluate efficacy safety regimen first line treatment advance NSCLC . Efficacy data collect The following evaluation conduct assess efficacy combination : - response rate RECIST criterion - disease free overall survival , TTP duration response Safety data collect The following evaluation conduct assess safety combination chemotherapy : • toxicity base NCI-CTCAE version 3.0 Statistical procedure In phase I portion , 9-18 patient enrol . The patient treat recommended dose level phase II also eligible response evaluation part phase II . The primary objective phase II study estimate efficacy safety combination therapy carboplatin , bortezomib bevacizumab first line therapy patient advance NSCLC . The primary endpoint response rate progression-free survival ( PFS ) . In phase II portion , optimal two-stage design phase II clinical trial describe Simon et al . utilized . Overall survival , progression free survival time progression estimate use Kaplan-Meier method . Time progression , progression free survival survival calculate date study entry .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Histologically confirm SCLC ( adeno large cell , anaplastic carcinoma bronchoalveolarcarcinoma ) . Patients squamouscell histology eligible extra thoracic peripheral lung lesion . Sputum cytology alone acceptable evidence cell type . Cytologic specimen obtain brushing , washing , needle aspiration define lesion acceptable . Mixed tumor categorize predominant cell type unless small cell anaplastic element present , case patient ineligible . Stage III B pleural effusion Stage IV disease Measurable disease . Age : 18 year old No history thrombotic , hemorrhagic , coagulopathy disorder INR &lt; 1.5 PTT great normal limit normal within 1 week prior registration . NB : subject lung cancer place anticoagulant therapy thrombotic event eligible study . No gross hemoptysis ( define bright red blood ½ teaspoon ) No CNS brain metastasis Laboratory Criteria ( complete &lt; 2 week enrollment ) : Hematologic : WBC &gt; 3500/mm3 ANC &gt; 1500/mm3 platelet count &gt; 100 000/ mm3 ; Hepatic : Total bilirubin &lt; 1.5 mg/dl Renal : Creatinine &lt; 1.5 mg/dl . calculate Creatinine clearance &gt; 45 ml/min ( NB : Urine protein : creatinine ratio exclusion criterion ) ECOG performance status &lt; 2 Be free active infection . Be available active follow . No prior chemotherapy metastatic disease . Be disease free &gt; 5 year prior second malignancy treat basal cell carcinoma squamous cell skin cancer , carcinoma situ cervix . Female subject postmenopausal ; surgically sterilize willing use acceptable method birth control duration study . Male subject agrees use acceptable method contraception duration study . CNS brain metastasis Patient = great Grade 2 peripheral neuropathy within 14 day enrollment . Known previous sensitivity reaction boron , mannitol , Patients know HIV positivity Myocardial infarction within 6 month prior enrollment New York Hospital Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Any ECG abnormality Screening document investigator medically relevant . Blood pressure &gt; 150/100 mmHG History myocardial infarction stroke within 6 month Clinically significant peripheral vascular disease Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 , anticipation need major surgical procedure course study . Minor surgical procedure fine needle aspiration core biopsy within 7 day prior day 0 Urine protein : Creatinine ratio &gt; 1.0 screen History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior Day 0 Serious , nonhealing wound , ulcer , bone fracture Lung carcinoma histology close proximity major vessel cavitation Female subject pregnant breastfeeding . Confirmation subject pregnant . Pregnancy test require postmenopausal surgically sterilize woman . Patient receive investigational drug 14 day enrollment expect participate experiment drug study study treatment . Serious medical psychiatric illness likely interfere participation clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>lung cancer , Carboplatin , bortezomib , Bevacizumab</keyword>
</DOC>